You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

docetaxel

Showing 1 - 25 of 1,353
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jun 16, 2023

Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)

Not yet recruiting
  • Prostate Cancer
  • Docetaxel
  • +2 more
  • Chicago, Illinois
    Northwestern University
Sep 27, 2023

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)

Recruiting
  • Serplulimab,Gastric Cancer, Adjuvant Therapy
  • Shanghai, China
    Zhang Zizhen
Mar 3, 2023

NSCLC Trial (SGN-B6A, docetaxel)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 21, 2023

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)

Recruiting
  • Metastatic Prostate Cancer
  • +2 more
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial (Standard ADT (androgen deprivation therapy), Standard Darolutamide,

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • Standard ADT (androgen deprivation therapy)
  • +2 more
  • (no location specified)
Jan 6, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Docetaxel
  • +3 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC Trial in China (Cadonilimab, Anlotinib, Docetaxel)

Recruiting
  • NSCLC Stage IV
  • +2 more
  • Hefei, Anhui, China
  • +4 more
Apr 15, 2023

Metastatic Prostatic Adenocarcinoma Trial in Charleston (Docetaxel, Degarelix)

Active, not recruiting
  • Metastatic Prostatic Adenocarcinoma
  • Charleston, South Carolina
    Medical University of South Carolina
Jan 30, 2023

NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Department of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023

Soft Tissue Sarcoma Trial in Winston-Salem (drug, radiation, procedure, other)

Recruiting
  • Soft Tissue Sarcoma
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Jan 26, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Breast Cancer Trial in Beijing (QL1701, Herceptin®, Docetaxel)

Active, not recruiting
  • Breast Cancer
  • Beijing, China
    Cancer Hospital,Chinese Academy of Medical Sciences
Nov 18, 2022

NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • MK-2870
  • +2 more
  • (no location specified)
Oct 3, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer Trial in Kyiv (Docetaxel, Oxaliplatin, Leucovorin)

Recruiting
  • Gastric Cancer
  • +10 more
  • Docetaxel
  • +3 more
  • Kyiv, Ukraine
    National Cancer Institute
Aug 31, 2023

Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)

Completed
  • Breast Neoplasms
  • Shanghai, Shanghai, China
    Ruijin Hospital
Oct 26, 2022

Locally Advanced Gastric Adenocarcinoma, Chemo Effect Trial in Hanzhou (Docetaxel, Tegafur-Gimeracil-Oteracil)

Recruiting
  • Locally Advanced Gastric Adenocarcinoma
  • Chemotherapy Effect
  • Hanzhou, Zhejiang, China
    Gastrointestinal Department of Second Affiliated Hospital of Zhe
Apr 2, 2023

Non Small Cell Lung Cancer Trial in Davis, Orlando, Columbus (ONC-392, Docetaxel)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Davis, California
  • +2 more
Jan 5, 2023

HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)

Recruiting
  • HER2 Positive Early Breast Cancer
  • Docetaxel
  • +5 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023

Prostate Cancer, Castration-resistant Prostate Cancer Trial in São Paulo (Docetaxel, Enzalutamide)

Active, not recruiting
  • Prostate Cancer
  • Castration-resistant Prostate Cancer
  • São Paulo, SP, Brazil
    Instituto do Câncer do Estado de São Paulo
Sep 14, 2022